Kenvue Inc. (KVUE) EBITDA
The ebitda for Kenvue Inc. (KVUE) is $2.94 Billion with a year-over-year change of +18.92%. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures a company's operating performance by removing non-cash charges and capital structure effects.
KVUE EBITDA Chart
Reported annual fiscal-period values; no daily interpolation.
KVUE Quarterly EBITDA Growth (YoY)
EBITDA growth vs the same quarter one year earlier, last 14 quarters.
Current EBITDA
$2.94B
$2.94 Billion
Year-over-Year Change
+18.92%
vs. $2.47B prior year
Historical Data
7
Years of data available
Annual EBITDA History
| Year | EBITDA | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.94B | +$467.00M | +18.92% |
| 2024 | $2.47B | $-707.00M | -22.27% |
| 2023 | $3.17B | $-106.00M | -3.23% |
| 2022 | $3.28B | $-375.00M | -10.26% |
| 2021 | $3.66B | $-78.00M | -2.09% |
| 2020 | $3.73B | +$626.00M | +20.14% |
| 2019 | $3.11B | — | — |
About Kenvue Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- CEO
- Kirk L. Perry